A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
← catalyst calendarNCT07361562 · readout ≤ 650 d
Sponsored by Cogent Biosciences, Inc. (industry) · COGT — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
100estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-30 | actual | When the study began enrolling |
| Primary completion | May 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor, Adult
- ERBB2 Altered Breast Cancer
- ERBB2 Gene Amplification
- HER2 Overexpression
- Non-Small Cell Lung Cancer
- HER2
Intervention
- Drug: CGT4255
Primary outcomes
what the primary-completion date above is the date OFIncidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Part A]
measured Approximately 12 months
Overall Response Rate [Part B and Part C]
measured Approximately 6 months
Permalink · COGT's whole pipeline · Catalyst calendar · Every registered study · What changed